#ATLL is classified into 4 clinical subtypes, namely acute, lymphomatous, chronic, and smoldering, as defined by Shimoyama criteria #HTLVaware#HTLVAware
HTLV research is massively underfunded.
Why?
Affected populations are often low-income
Most carriers are asymptomatic
It lacks “urgency”
But neglect has a cost — in lives and futures. #HTLV#HTLVaware#GlobalHealth
Silva et al. show that HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) shares key inflammatory and neurodegenerative pathways with progressive MS, highlighting its value as a model of chronic inflammation-driven neurodegeneration. https://t.co/9Fcr1z4iF9
This new paper reveals how integrated in vitro and multi-cohort cross-omics analyses uncover a RelA-dependent epithelial mechanism driving monocyte recruitment and differentiation in HTLV-1–associated lung pathology
#Immunology#MolecularMedicine#HTLV1
➡️https://t.co/XE8mEjSnvT
Single-cell insights reveal how “periodic” TCR signalling shapes self-reactive T cells, and how HTLV-1 exploits this pathway. A fresh model with implications for cancer and immunotherapy. 🧬
Read here: https://t.co/jqPoZ7ATmo
#Immunology#Tcells#HTLV1
🎯 Targeted maternal screening for HTLV-1 could lower rates of adult T-cell #Leukemia#Lymphoma, a rare & fatal cancer.
🗨️ “This is a preventable cancer,” Dr. Paulo S. Pinheiro @SylvesterCancer@umiamimedicine said.
“The opportunity is there.” https://t.co/m0sc0Jg9Sp
HAM/TSP, the spinal cord disease caused by HTLV-1, can leave people unable to walk. Slowly. Progressively. With almost no treatment options. This is real. #HTLVAware#HTLV
HTLV-1 causes Adult T-cell Leukemia/Lymphoma, one of the most aggressive blood cancers known. It deserves far more funding than it receives. #HTLV#HTLVaware
Not all viruses behave the same. With Human T-lymphotropic virus, the majority stay asymptomatic, but a small percentage can develop serious disease years later. #HTLVaware
How do you test for #HTLV?
The presence of HTLV can be detected by a blood test. HTLV infection does not show up in routine blood tests such as those requested by your family doctor or routine hospital tests #HTLVaware
Dr. Damien Purcell (GVN; #UniversityofMelbourne) spoke at #GVNAnnualMeeting2026 on 3/4/26, highlighting HTLV-1 burden in endemic populations and the need for improved surveillance and targeted interventions.
📢 1st paper out now in our Special Issue Trends in Hepatitis Virus!
Prevalence of HTLV-1/2 in HCV-infected individuals in Belém do Pará, Brazil
https://t.co/adMYtpk8ep
Low but relevant coinfection rate supports integrated screening in northern Brazil.
#HCV#HTLV#Epidemiology
Dr. Robert Gallo, Co-founder and Int. Scientific Director of the GVN and GVN COE director at @USFHealth's ITVI, spoke during the Oncogenesis and Retroviruses panel at #GVNAnnualMeeting2026 on 3/4/26, highlighting the need for increased research & targeted interventions for HTLV.
Dr. Masao Matsuoka (#KumamotoUniversity) spoke at #GVNAnnualMeeting2026 on 3/4/26, highlighting how earlier HTLV vaccine studies showed transmission could potentially be blocked and could inform future prevention strategies in endemic regions.
Read: https://t.co/3828pn7DNg
Dr. Yutaka Tagaya (GVN; @USFHealth ITVI) spoke at #GVNAnnualMeeting2026 on 3/4/26, discussing HTLV vaccine development and the challenge of defining preventive versus therapeutic strategies and target populations in endemic regions.
Read the release: https://t.co/nyo8hw53gH
"Integrated genetic analyses identified T-cell neoplasms other than adult T-cell leukemia/lymphoma in HTLV-1 carriers" Read in Blood Advances: https://t.co/SB4hHQICEs
HTLV isn’t new — it’s just overlooked. Early testing and education could prevent transmission and protect future generations. Let’s start talking about it. #HTLVaware#HTLV